ReviewOncology (Williston Park, N.Y.)2014
Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.
Review in Oncology (Williston Park, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Combining precision oncology and immunotherapy by targeting the MALT1 protease.Journal for immunotherapy of cancer · 2022Review
- Assignment of IVL-Methyl side chain of the ligand-free monomeric human MALT1 paracaspase-IgLBiomolecular NMR assignments · 2022Article
- Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Molecular Subtypes, Apoptosis and Proliferation Status in Indonesian Diffuse Large B-Cell Lymphoma CasesAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.Journal of hematology · 2017Review
- Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.Annals of eye science · 2017Article
- Article
- Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.British journal of cancer · 2015Article
- Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP.Blood research · 2014Article
- Cell of Origin Classification of Diffuse Large B-Cell Lymphoma.Journal of microscopy and ultrastructureArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
In recent years, we have made huge strides in our understanding of the molecular complexity of diffuse large B-cell lymphoma (DLBCL). New technologies, such as gene expression profiling, RNA interference screening, and DNA sequencing, have identified several new signaling pathways and therapeutic targets for drug development. While we once considered DLBCL to be a single disease entity, recent insights have helped identify the existence of at least three distinct molecular diseases: a germinal center B-cell-like subtype, an activated B-cell-like subtype, and a primary mediastinal B-cell lymphoma subtype. All three subtypes originate from different stages of B-cell differentiation and are characterized by distinct mechanisms of oncogenic activation. This classification of DLBCL has laid the foundation for the development of new agents and novel strategies that target individual subtypes.
Indexed as
Identifiers
24839807PMC7722987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.